

David Abasiwani Alagpulinsa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6576587/publications.pdf>

Version: 2024-02-01

14
papers

317
citations

1307594

7
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Alginate-microencapsulation of human stem cell-derived $\hat{1}^2$ cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. <i>American Journal of Transplantation</i> , 2019, 19, 1930-1940.	4.7	94
2	A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. <i>Frontiers in Oncology</i> , 2014, 4, 289.	2.8	69
3	A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 241-250.	4.1	58
4	Harnessing CXCL12 signaling to protect and preserve functional $\hat{1}^2$ -cell mass and for cell replacement in type 1 diabetes. , 2019, 193, 63-74.		18
5	Genomic Instability in Multiple Myeloma. <i>Trends in Cancer</i> , 2020, 6, 858-873.	7.4	18
6	Metabolomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation. <i>Biomaterials</i> , 2021, 268, 120482.	11.4	18
7	A peptide nucleic acid targeting nuclear <i>RAD51</i> sensitizes multiple myeloma cells to melphalan treatment. <i>Cancer Biology and Therapy</i> , 2015, 16, 976-986.	3.4	14
8	Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3968-3972.	5.2	11
9	A Peptide Nucleic Acid Targeting Nuclear Rad51 Sensitizes Myeloma Cells to Melphalan Chemotoxicity Both in Vitro and in Vivo. <i>Blood</i> , 2014, 124, 3529-3529.	1.4	5
10	Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. <i>Blood</i> , 2014, 124, 479-479.	1.4	5
11	Advances in understanding the molecular basis of clonal hematopoiesis. <i>Trends in Molecular Medicine</i> , 2022, 28, 360-377.	6.7	5
12	Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance. <i>Blood</i> , 2015, 126, 2420-2420.	1.4	2
13	Abstract 2400: Dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs), impairs homologous recombination, abrogates G2 checkpoint arrest and sensitizes myeloma cells to PARP inhibition. , 2014, , ,		0
14	Flap Structure-Specific Endonuclease 1 (FEN1) May be a Key Mediator of Genome Instability in Myeloma: A Cellular Vulnerability with Potential Therapeutic Significance. <i>Blood</i> , 2016, 128, 4440-4440.	1.4	0